about
Peptide ligands stabilized by small moleculesSingle cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokinesPost-translational modification of genetically encoded polypeptide libraries.Structurally diverse cyclisation linkers impose different backbone conformations in bicyclic peptides.Measuring net protease activities in biological samples using selective peptidic inhibitors.Bicyclization and tethering to albumin yields long-acting peptide antagonists.Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor.Protein Engineering and Selection Using Yeast Surface Display.Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumors.Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.Enzymatic cyclisation of peptides with a transglutaminase.Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis.Boosting the Sensitivity of Ligand–Protein Screening by NMR of Long-Lived StatesChemical Macrocyclization of Peptides Fused to Antibody Fc FragmentsThe crystal structure of CagS from theHelicobacter pyloripathogenicity islandTriggering positive selection of germinal center B cells by antigen targeting to DEC-205Molecular evolution of peptides by yeast surface display technologyNon-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeuticsThiol-to-amine cyclization reaction enables screening of large libraries of macrocyclic compounds and the generation of sub-kilodalton ligands
P50
Q27688961-F30C905D-CB71-4AAE-B1A6-E9BC0BF408DCQ33668200-A9A0B990-10B0-431F-9A8D-059D7C926E54Q33871949-C89E5FA7-8727-4EE9-A4D0-35F8EF9899DEQ34227953-E27D7712-26E6-464C-AFA4-D4541BB90AE5Q34253075-024FC432-39D9-427F-ADA7-8CA23D5A01B0Q34454138-815A4E31-E0A1-4408-9BDA-0FA9930C6A3DQ35437978-B4D7F0CC-DAEF-4377-ACA9-79323078E88AQ35652476-E9BD6A3B-4C14-48C7-8FA0-188DEC68004EQ35659177-336FFE09-A805-41A4-BACE-4E5F3020420DQ38941702-F2AE0127-4C9B-4EDF-9AAF-7B59DD64613BQ44944214-A059A508-F23F-4F07-BE57-E77154779DADQ46258943-A6889442-A5A8-4B2C-8F0F-40FA5139B05BQ52589113-14F846CD-8327-45B0-8E78-DAFBCC507446Q58217764-4CD424E5-1D89-4CC5-B3D4-3F1FC9F9E7F5Q61058384-5A23AEB6-8103-4B1C-BA1E-F665726B634EQ62448424-6B64B791-614A-4190-9F7D-E418B337420DQ87043740-52897BDF-D2CC-4DAA-9069-0A41F6EC3869Q91709541-D54BF55E-D3D7-40F2-8F1D-967F584A7D05Q92485709-C55E073A-2ECC-4D6C-997C-96022F1815B0Q92924472-5DA22338-32C7-420C-84CC-1B8063B5C499
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Alessandro Angelini
@en
Alessandro Angelini
@nl
type
label
Alessandro Angelini
@en
Alessandro Angelini
@nl
prefLabel
Alessandro Angelini
@en
Alessandro Angelini
@nl
P108
P31
P496
0000-0001-5923-3843